UCB SA (UCBJY)
OTCMKTS · Delayed Price · Currency is USD
151.96
+1.25 (0.83%)
Mar 10, 2026, 3:52 PM EST
UCB SA Revenue
In the year 2025, UCB SA had annual revenue of 7.74B EUR with 25.83% growth. UCB SA had revenue of 4.25B in the half year ending December 31, 2025, with 59.74% growth.
Revenue
7.74B EUR
Revenue Growth
+25.83%
P/S Ratio
6.42
Revenue / Employee
900.12K EUR
Employees
8,600
Market Cap
58.37B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.74B | 1.59B | 25.83% |
| Dec 31, 2024 | 6.15B | 970.00M | 18.72% |
| Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
| Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 115.29K |
UCB SA News
- 7 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 8 days ago - UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... - GuruFocus
- 8 days ago - Full Year 2025 Ucb SA Earnings Call Transcript - GuruFocus
- 8 days ago - Best Income Stocks to Buy for March 2nd - Nasdaq
- 20 days ago - Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight - GuruFocus
- 26 days ago - Best Income Stocks to Buy for February 12th - Nasdaq
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire